Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Endometrial Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Histological confirmed endometrial cancer of the endometrioid, serous, carcinosarcoma or undifferentiated type. 2) Completed a single line of at least 12 weeks of taxane-platinum combination therapy (not including adjuvant or neoadjuvant therapy), and achieved partial remission (PR) or complete remission (CR) according to RECIST version 1.1. 3) Primary stage IV disease or intial relapsed stage I-IV endometrial cancer.

You may not be eligible for this study if the following are true:

  • 1) Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas. 2) Previous treatment with an XPO1 inhibitor. 3) Previous treatment with an anti-PD1 or anti-PD-L1 inhibitor.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.